Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849662 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
A Phase 1 study of Neurofibromatosis 1 and Leukemia, Juvenile Myelomonocytic, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 4
- Study locations
NCT05849662 is a Phase 1 study of Neurofibromatosis 1 and Leukemia, Juvenile Myelomonocytic that is actively recruiting participants, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 58 participants, below the 1,033-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05849662, a Phase 1 study of Neurofibromatosis 1 and Leukemia, Juvenile Myelomonocytic, is actively recruiting participants, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 4
- Study locations
Study Summary
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Azacitidine
- DRUG Cytarabine
- DRUG Trametinib
Study Locations (4)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2024-10-11 |
| Est. Completion | 2029-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05849662
The ClinicalTrials.gov registry entry for NCT05849662 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,033-participant average among 24 other Neurofibromatosis 1 trials with a reported enrollment target (94% lower). The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neurofibromatosis 1 appearing as the primary indexed condition, and to 4 interventions - of which Fludarabine is the first listed.
NCT05849662 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, District of Columbia, Ohio.
Frequently Asked Questions
What is clinical trial NCT05849662 about?
NCT05849662 is a clinical study titled "A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia". This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, flud...
What is the current status of trial NCT05849662?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2024-10-11. Estimated completion is 2029-12.
What conditions does trial NCT05849662 study?
This clinical trial studies the following conditions: Neurofibromatosis 1, Leukemia, Juvenile Myelomonocytic, JMML, JCML, CBL Syndrome.
What interventions are being tested in trial NCT05849662?
The interventions under investigation include: Fludarabine (DRUG), Azacitidine (DRUG), Cytarabine (DRUG), Trametinib (DRUG).
Who is sponsoring clinical trial NCT05849662?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849662 being conducted?
This trial has 4 study locations across California, District of Columbia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurofibromatosis 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
RECRUITING · Phase 1
-
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
ACTIVE NOT RECRUITING · Phase 1
-
NF-1, Nutraceutical Intervention
ACTIVE NOT RECRUITING · Phase 1
-
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
COMPLETED · Phase 1
-
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.